Agreement provides MSD with options to license Evaxion’s preclinical, AI-designed vaccine candidates EVX-B2 and EVX-B3 Evaxion will host a conference call and webcast to discuss the agreement on ...
Evaxion Biotech (EVAX) shares gained roughly 17% in early trade on Thursday after the company announced an expansion of its vaccine development collaboration with MSD (NYSE:MRK) (tradename of ...
COPENHAGEN - Evaxion Biotech A/S (NASDAQ: EVAX), a clinical-stage TechBio company, has entered into an option and license agreement with pharmaceutical giant MSD, known as Merck & Co., Inc.